Enliven Therapeutics Inc. (ELVN) Insider Trading
Total insider buys:
- $0.00
Total insider sells:
- $57,302,977.10
Most recent insider trade:
- April 21, 2025
Most active insider trader:
- Benjamin Hohl
Trader Name | Date | Title | Amount | Price | Type | Total Value |
---|---|---|---|---|---|---|
April 21, 2025 | Insider | 5,000 | $16.07 | Sell | $80,350.00 | |
April 17, 2025 | CEO | 5,000 | $16.42 | Sell | $82,100.00 | |
April 7, 2025 | COO | 6,667 | $18.04 | Sell | $120,272.68 | |
March 27, 2025 | CFO | 3,250 | $21.33 | Sell | $69,322.50 | |
March 24, 2025 | CFO | 1,000 | $22.50 | Sell | $22,500.00 | |
March 19, 2025 | Insider | 12,500 | $20.61 | Sell | $257,625.00 | |
March 17, 2025 | CEO | 12,500 | $20.83 | Sell | $260,375.00 | |
March 7, 2025 | COO | 6,667 | $21.44 | Sell | $142,940.48 | |
Feb. 27, 2025 | CFO | 3,250 | $20.41 | Sell | $66,332.50 | |
Feb. 7, 2025 | COO | 6,667 | $21.93 | Sell | $146,207.31 | |
Feb. 5, 2025 | CFO | 1,000 | $22.52 | Sell | $22,520.00 | |
Jan. 27, 2025 | CFO | 3,250 | $21.59 | Sell | $70,167.50 | |
Jan. 7, 2025 | COO | 21,700 | $24.18 | Sell | $524,706.00 | |
Jan. 3, 2025 | CFO | 1,000 | $25.04 | Sell | $25,040.00 | |
Dec. 30, 2024 | CFO | 900 | $22.51 | Sell | $20,259.00 | |
Dec. 27, 2024 | CFO | 3,350 | $22.15 | Sell | $74,202.50 | |
Nov. 27, 2024 | CFO | 5,250 | $24.89 | Sell | $130,672.50 | |
Oct. 28, 2024 | CFO | 6,250 | $28.56 | Sell | $178,500.00 | |
Oct. 18, 2024 | Insider | 847 | $30.00 | Sell | $25,410.00 | |
Oct. 18, 2024 | CEO | 924 | $30.00 | Sell | $27,720.00 | |
Oct. 18, 2024 | COO | 716 | $30.00 | Sell | $21,480.00 | |
Oct. 18, 2024 | CFO | 814 | $30.00 | Sell | $24,420.00 | |
Oct. 18, 2024 | Director | 817 | $30.00 | Sell | $24,510.00 | |
Oct. 15, 2024 | Director | 1,270 | $27.67 | Sell | $35,140.90 | |
Oct. 9, 2024 | CEO | 16,710 | $28.15 | Sell | $470,386.50 | |
Oct. 9, 2024 | Insider | 37,878 | $28.16 | Sell | $1,066,644.48 | |
Oct. 8, 2024 | Director | 10,420 | $28.17 | Sell | $293,531.40 | |
Oct. 7, 2024 | CFO | 1,270 | $27.51 | Sell | $34,937.70 | |
Oct. 7, 2024 | Insider | 2,707 | $27.61 | Sell | $74,740.27 | |
Oct. 7, 2024 | CEO | 2,730 | $27.50 | Sell | $75,075.00 | |
Oct. 4, 2024 | CEO | 12,206 | $27.51 | Sell | $335,787.06 | |
Oct. 4, 2024 | Director | 2,825 | $27.51 | Sell | $77,715.75 | |
Oct. 4, 2024 | Insider | 7,522 | $27.51 | Sell | $206,930.22 | |
Oct. 4, 2024 | CFO | 10,218 | $27.51 | Sell | $281,097.18 | |
Oct. 1, 2024 | CEO | 526 | $27.54 | Sell | $14,486.04 | |
Oct. 1, 2024 | Director | 518 | $27.54 | Sell | $14,265.72 | |
Oct. 1, 2024 | Insider | 527 | $27.54 | Sell | $14,513.58 | |
Sept. 30, 2024 | CFO | 2,000 | $25.33 | Sell | $50,660.00 | |
Sept. 27, 2024 | CFO | 4,250 | $24.27 | Sell | $103,147.50 | |
Aug. 29, 2024 | Insider | 12,000 | $22.49 | Sell | $269,880.00 | |
Aug. 27, 2024 | CFO | 4,250 | $22.54 | Sell | $95,795.00 | |
Aug. 26, 2024 | CEO | 12,000 | $22.89 | Sell | $274,680.00 | |
Aug. 15, 2024 | Director | 1,270 | $23.25 | Sell | $29,527.50 | |
July 31, 2024 | Insider | 3,099 | $27.56 | Sell | $85,408.44 | |
July 31, 2024 | CFO | 991 | $27.53 | Sell | $27,282.23 | |
July 31, 2024 | CEO | 2,270 | $27.56 | Sell | $62,561.20 | |
July 31, 2024 | Director | 1,702 | $27.51 | Sell | $46,822.02 | |
July 29, 2024 | Insider | 12,000 | $26.70 | Sell | $320,400.00 | |
July 29, 2024 | CFO | 5,250 | $26.68 | Sell | $140,070.00 | |
July 25, 2024 | CEO | 12,000 | $24.92 | Sell | $299,040.00 |
Insiders are selling Enliven Therapeutics Inc. stock.
The insider traders at Enliven Therapeutics Inc. are: Benjamin Hohl, Samuel Kintz, Anish Patel, Richard A Heyman, Joseph P Lyssikatos, Joseph P. Lyssikatos, Rahul D Ballal, 5Am Partners Vi, Llc, and Rishi Gupta
The most active insider trader at Enliven Therapeutics Inc. is Benjamin Hohl with 30 trades.
Rishi Gupta has sold the most Enliven Therapeutics Inc. stock with a total value of $45,754,524.00.
The most recent insider trade for Enliven Therapeutics Inc. was on April 21, 2025.
The single biggest insider sell for Enliven Therapeutics Inc. was from Rishi Gupta with a total value of $22,877,262.00 on May 16, 2024.